REMoDL-A Trial
https://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/remodla.page Add to Contact List

The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).

Contact Information

Last Updated: 02/14/2022

Annual Statistics